Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837328 · ClinicalTrials.gov registry record · Phase 2
Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
A Phase 2 study of Premature Atrial Contraction, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT02837328 is a Phase 2 study of Premature Atrial Contraction that has completed, run by University of Minnesota. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02837328, a Phase 2 study of Premature Atrial Contraction, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral Magnesium Supplement
Study Locations (1)
Minnesota
- University of Minnesota - Twin Cities - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02837328
The ClinicalTrials.gov registry entry for NCT02837328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Premature Atrial Contraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02837328 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02837328 about?
NCT02837328 is a clinical study titled "Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias". The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
What is the current status of trial NCT02837328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-03-01. Estimated completion is 2017-09-15.
What conditions does trial NCT02837328 study?
This clinical trial studies the following conditions: Premature Atrial Contraction.
What interventions are being tested in trial NCT02837328?
The interventions under investigation include: Placebo (DRUG), Oral Magnesium Supplement (DRUG).
Who is sponsoring clinical trial NCT02837328?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02837328 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Atrial Contraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.